Drug Profile
Research programme: immunological disorders therapeutics - Undisclosed company
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Unknown
- Class Immunotherapies; Peptides
- Mechanism of Action Immunosuppressants; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Hypersensitivity
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Allergy in Unknown (Parenteral)
- 28 May 2021 No recent reports of development identified for research development in Autoimmune-disorders in Unknown (Parenteral)
- 25 Apr 2017 Early research in Hypersensitivity and Autoimmune disorders (Parenteral)